Arthritis

Chicago, IL

77 Arthritis Trials near Chicago, IL

Power is an online platform that helps thousands of Arthritis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Zasocitinib for Psoriatic Arthritis

Orland Park, Illinois
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1088 Participants Needed

Tulisokibart for Rheumatoid Arthritis

Orland Park, Illinois
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

182 Participants Needed

ABP-745 for Gout

Naperville, Illinois
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

380 Participants Needed

Total Knee Replacement for Osteoarthritis

Aurora, Illinois
The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22+

800 Participants Needed

Hip Replacement Liners for Osteoarthritis

South Bend, Indiana
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

300 Participants Needed

Knee Replacement for Osteoarthritis

Rockford, Illinois
The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Persona fixed bearing knee implants used in total knee arthroplasty. The assessment will include implant survivorship and clinical performance.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

737 Participants Needed

Abatacept vs Adalimumab for Rheumatoid Arthritis

Milwaukee, Wisconsin
The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an inadequate methotrexate response.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

338 Participants Needed

GLP-1 Analogs for Psoriatic Arthritis

Milwaukee, Wisconsin
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes. The main objectives it aims to answer are: To assess disease outcomes of PsA patients undergoing treatment for concomitant obesity and type 2 diabetes with GLP-1 analogs vs nutrition counseling. To assess effectiveness as measured by clinical and patient reported outcome measures in patients treated with GLP-1 and nutrition counseling. Participants will be randomized to receive a GLP-1 or nutrition counseling. Participants will be asked to come to the study center at most four times during a 24-week period. During this time participants will be asked to fill out questionnaires, receive a physical exam, and have their blood drawn.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4

22 Participants Needed

CAPPA for Chronic Knee Pain

Milwaukee, Wisconsin
The goal of this clinical trial is to learn if a brief health coaching intervention based on an approach known as brief action planning + Fitbit can increase physical activity in employees with chronic knee symptoms who work for Advocate Aurora Health. The main questions it aims to answer are: * Will a greater proportion of people in the health coaching intervention increase physical activity to at least 150 minutes of moderate-to-vigorous physical activity per week than a group of people with an attention-control intervention (Fitbit+health education coaching)? * Can we predict who will not increase physical activity levels to at least 150 minutes of moderate-to-vigorous physical activity per week by the end of the study (3 and 6 months) based upon Fitbit data captured over the first four weeks? Researchers will compare a health education coaching intervention + Fitbit to see if providing a Fitbit + attention control will increase physical activity to at least 150 minutes of moderate-to-vigorous physical activity per week among members of the attention-control group. Participants will engage in * Online study orientation and question and answer session * Three assessment sessions (baseline, 3 months, 6 months) * A 12 week intervention with no less than four (4) and no more than twelve (12) health coaching sessions. Physical activity health coaching will make action plans for health coaching. Health education coaching will focus on educating participants on non-physical activity factors related to a comprehensive management of chronic knee symptoms, such as managing fatigue, sleep hygiene, mindfulness, etc.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

100 Participants Needed

Hip Resurfacing for Arthritis

Grafton, Wisconsin
The purpose of this study is to meet a PMA condition of approval of the BHR System. The study will evaluate the long term safety and effectiveness of the BHR system in patients with non-inflammatory and inflammatory arthritis.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21 - 75

360 Participants Needed

Ankle Implant for Arthritis

Grand Rapids, Michigan
This trial studies a special ankle implant for patients needing ankle surgery. It aims to see how well the implant works in reducing pain and improving function. The implants have been developed to improve stability and longevity, with advancements in design and materials.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

120 Participants Needed

Aptis PRUJ Prosthesis for Arthritis

Carmel, Indiana
A Prospective, Multi-Center, Single-Arm Clinical Trial of the safety and effectiveness of the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint disorders
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

84 Participants Needed

Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis

Carmel, Indiana
This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

924 Participants Needed

CTM Injection for Shoulder Osteoarthritis

Indianapolis, Indiana
CTM Biomedical markets and distributes decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act. The goal of this study is to determine the success rate of a single, image guided glenohumeral CTM injection (for radiographically confirmed glenohumeral osteoarthritis at follow up intervals of 1, 2, 3, 4, 6, 9, and 12 months. This will be measured using the Likert Pain Scale (LPS) and Oxford Shoulder Score (OSS). Secondary goals are to identify if certain demographic or imaging factors exist that predict early symptom recurrence requiring additional intervention, defined as a second connective tissue matrix injection, a subsequent corticosteroid injection, or arthroplasty.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

30 Participants Needed

CTM Injection for Thumb Arthritis

Indianapolis, Indiana
The goal of this study is to determine the success rate of a single Carpometacarpal (CMC) thumb injection after arthroplasty surgery for primary osteoarthritis of the CMC joint.

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

50 Participants Needed

Tocilizumab for Giant Cell Arteritis

Chicago, Illinois
This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance versus withdrawal in Giant cell arteritis (GCA) patients who are in remission after at least 12 months of high dose TCZ treatment. Eligible participants will also have discontinued glucocorticoids (e.g., prednisone (or equivalent)) entirely at least three months before randomization. High dose TCZ treatment includes 6-8 mg/kg intravenously (IV) monthly or 162 mg subcutaneously (SC) weekly, which are two forms of administration that are commonly used in clinical practice and are equally efficacious in controlling GCA This research study has three parts: 1. The screening phase (up to 42 days) consists of collecting information about your health and your GCA, a physical exam, and blood tests to see If you qualify to enroll in the study 2. The study treatment phase (withdrawal/step down dosing phase study months 0 - 18) consists of you either completely stopping or decreasing your current dose of tocilizumab while collecting information about your health and your GCA as well as blood samples every two months at clinic visits 3. The safety follow-up phase (months 19-30) consists of collecting information about your health and your GCA as well as blood samples every three months The primary objective is to determine the rate of disease relapse at 18 months in participants with GCA who receive low-dose TCZ compared to those who discontinue TCZ
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:50+

78 Participants Needed

Upadacitinib for Giant Cell Arteritis

Chicago, Illinois
This trial tests if upadacitinib, combined with reducing steroid doses, helps people with giant cell arteritis achieve and maintain remission by reducing inflammation. Upadacitinib has been approved for the treatment of rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis, and is under investigation for other conditions.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:50+

429 Participants Needed

Why Other Patients Applied

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I’ve tried several meds without too much relief. Injections only work on my right knee but not much on the left knee. My pain is nearly unbearable at this point. Hoping to learn about what promising drugs exist in trials."

YV
Arthritis PatientAge: 61

"I’m allergic to so many standard arthritis drugs, so I've been researching some of the newest ones still in the research phase. I'm hoping to find out if I'd be a good match—it would be great to find something that works (and, if not, at least contribute to the cause)."

TJ
Arthritis PatientAge: 79

"I have been struggling with severe knee pain since my service in the military. I am only 52! I miss doing the things I used to do."

NA
Arthritis PatientAge: 55

"I've been 17+ years in pain with bilateral osteoarthritis. PRP and HA injections have not helped. Physical therapy has helped only to a certain degree. I'm looking for new treatment options before considering replacement. "

RH
Arthritis PatientAge: 39
123

Know someone looking for new options? Spread the word

Match to a Trial